Group 1: Dividend Indices - The Low Volatility Dividend Index (H30269.CSI) includes 50 securities with good liquidity, continuous dividends, moderate payout ratios, positive growth in dividends per share, high dividend yields, and low volatility, with a one-year dividend yield of 4.09% as of December 1 [1] - The Dividend Quality Index (931468.CSI) consists of 50 securities that continuously pay cash dividends, have high payout ratios, and exhibit high profitability, with a one-year dividend yield of 3.42% as of December 1 [1] Group 2: Company Dividend Announcements - Tongxingbao announced a cash dividend of 1.50 RMB per 10 shares (tax included), with a record date of December 5, 2025, and an ex-dividend date of December 8, 2025 [1] - Shanghai Ailu announced a cash dividend of 0.40 RMB per 10 shares (tax included), with a record date of December 4, 2025, and an ex-dividend date of December 5, 2025 [2] - Aiwei Technology announced a cash dividend of 0.054 RMB per share (tax included), with a record date of December 5, 2025, and an ex-dividend date of December 8, 2025 [2] - Meibang Co. announced a cash dividend of 0.05 RMB per share (tax included), with a record date of December 9, 2025, and an ex-dividend date of December 10, 2025 [2] - Aidi Precision announced a cash dividend of 0.10 RMB per share (tax included), with a record date of December 5, 2025, and an ex-dividend date of December 8, 2025 [3] - Dingdian Software announced a cash dividend of 0.20 RMB per share (tax included), with a record date of December 9, 2025, and an ex-dividend date of December 10, 2025 [3] - Jingjin Equipment announced a cash dividend of 0.50 RMB per share (tax included), with a record date of December 5, 2025, and an ex-dividend date of December 8, 2025 [3] - Lujiazui announced a cash dividend of 0.0633 RMB per share (tax included), with a record date of December 9, 2025, and an ex-dividend date of December 10, 2025 [4] - Zhongzhi Technology announced a cash dividend of 0.80 RMB per 10 shares (tax included), with a record date of December 5, 2025, and an ex-dividend date of December 8, 2025 [4] - Dahua Co. announced a cash dividend of 1.850000 RMB per 10 shares (tax included), with a record date of December 8, 2025, and an ex-dividend date of December 9, 2025 [4] - Sun Paper announced a cash dividend of 1.00 RMB per 10 shares (tax included), with a record date of December 9, 2025, and an ex-dividend date of December 10, 2025 [5]

Core Points - The company announced a cash dividend of RMB 0.054 per share for the first three quarters of 2025 [1][2] - The profit distribution plan was approved by the board on October 29, 2025, following authorization from the annual shareholders' meeting on May 23, 2025 [1][2] Distribution Plan - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [2][3] - The total number of shares eligible for distribution is 67,278,000 after excluding 722,000 shares held in the company's repurchase account, resulting in a total cash dividend of RMB 3,633,012 [3][5] Dividend Calculation - The cash dividend per share is calculated as approximately RMB 0.0534, based on the total shares participating in the distribution [5] - The reference price for ex-dividend trading will be adjusted by subtracting the cash dividend from the previous closing price [4][5] Implementation Details - Cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited to eligible shareholders [6][8] - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the trading is completed [6] Taxation Information - Individual shareholders holding shares for over one year will not be subject to personal income tax on the dividend, while those holding for less than one year will have taxes calculated upon the sale of shares [9][10] - For qualified foreign institutional investors (QFII), a 10% withholding tax will be applied, resulting in a net dividend of RMB 0.0486 per share [10][11]

的法律意见书 湖南启元律师事务所 关于爱威科技股份有限公司差异化分红事项 ·湖南启元律师事务所· HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：0731-82953778 传真：0731-82953779 网站：http://www.qiyuan.com 二〇二五年十一月 湖南启元律师事务所 关于爱威科技股份有限公司差异化分红事项 的法律意见书 致：爱威科技股份有限公司 第一部分 引言 湖南启元律师事务所（以下简称"本所"）受爱威科技股份有限公司（以 下简称"公司"或"爱威科技"）的委托，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所上市公司回购股份实施细则》（以下简称"《回购细则》"）、 《上海证券交易所股票上市规则》（以下简称"《上市规则》"）等法律、行政 法规、部门规章、其他规范性文件的有关规定以及《爱威科技股份有限公司章程》 （以下简称"《公司章程》"），就公司 2025 年前三季度利润分配所涉及的差 异化分红（以下简称"本次差异化分红"） ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-048 爱威科技股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的有关规定，上市公司回购专用账户中的股份，不享有股东会 表决权、利润分配、公积金转增股本、认购新股和可转换公司债券等权利。故公 司回购专用证券账户持有股份不参与本次利润分配。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/12/5 | 2025/12/8 | 2025/12/8 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经爱威科技股份有限公司（以下简称"公司"）2025 年 5 月 23 日的2024年年度股东会授权，2025 年 10 月 29 日召开的第五届董事会第六 次会议审议通过。 二、 分配方案 1. 发放年度：2025年前三季度 2. 分派对象： 截至股权 ...

Core Viewpoint - The company emphasizes its commitment to research and development (R&D), indicating a 7.28% year-on-year increase in R&D investment for the first three quarters of 2025, despite a slight decrease in the proportion of R&D investment to revenue due to overall revenue growth [1] Group 1 - The company has maintained an R&D investment revenue ratio above 10% since its listing [1] - Future plans include continuing high-intensity R&D investments to enhance core competitiveness [1]

Group 1 - The core viewpoint of the news is that Aiwei Technology has shown a slight increase in stock price and has reported significant financing activities, indicating investor interest despite a low financing balance relative to market value [1] - As of November 14, Aiwei Technology's financing balance is 40.86 million yuan, accounting for 2.09% of its market capitalization, which is below the 50th percentile level over the past year, indicating a low financing position [1] - The company has not engaged in any short selling activities on November 14, with a short selling balance of 0, which is at a high level compared to the 90th percentile over the past year [1] Group 2 - As of September 30, Aiwei Technology reported a total of 4,350 shareholders, an increase of 6.46% from the previous period, while the average circulating shares per person decreased by 6.07% [2] - For the period from January to September 2025, Aiwei Technology achieved operating revenue of 171 million yuan, representing a year-on-year growth of 11.63%, and a net profit attributable to shareholders of 29.24 million yuan, up 16.35% year-on-year [2] - Since its A-share listing, Aiwei Technology has distributed a total of 40.73 million yuan in dividends, with 20.33 million yuan distributed over the past three years [3]

Policy Developments - Jiangxi Province is promoting the development of brain-computer interface medical devices, emphasizing the need for regulatory compliance and collaboration among industry players to seize opportunities in emerging technologies [1] - The market for brain-computer interface medical devices is noted to have significant potential, with a strong development momentum in Jiangxi Province [1] Medical Device Approvals - In October, the National Medical Products Administration approved 204 medical device products, including 173 domestic Class III devices, 10 imported Class III devices, and 21 imported Class II devices [2] Pharmaceutical Logistics - The Shanghai Municipal Drug Administration encourages the development of modern pharmaceutical logistics, advocating for improved storage and management systems to enhance operational efficiency and reduce costs [3] Drug Approvals - Fangsheng Pharmaceutical announced that its Indobufen tablets received a drug registration certificate from the National Medical Products Administration, allowing for production [4] - Saito Bio's application for the chemical raw material drug Mometasone Furoate has been approved, indicating its use in treating asthma and skin conditions [5] - Tianyao Pharmaceutical received a drug registration certificate for Metoclopramide injection, which is used for treating nausea and vomiting [6] Capital Market Activities - Yingsi Intelligent submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for its AI-driven drug development initiatives [7][8] - Rejuve Bio plans to repurchase shares worth between 100 million and 200 million yuan to support employee stock ownership plans [9] Industry Developments - AstraZeneca's Baxdrostat demonstrated significant reductions in 24-hour average systolic blood pressure in treatment-resistant hypertension patients during the Bax24 Phase III trial, achieving a reduction of 14.0 mmHg compared to placebo [10][11] - The drug showed good overall tolerability and consistent safety profiles, with a notable percentage of patients achieving target blood pressure levels [11] - Maiwei Bio's IL-11 monoclonal antibody 9MW3811 received approval for Phase II clinical trials targeting pathological scars, marking it as the first IL-11 targeted drug to enter clinical trials for this indication [12] - Aiwei Technology's subsidiary obtained a medical institution practice license, enabling it to provide third-party medical testing services [13] - Anke Bio signed an exclusive agency framework agreement with Boshengji for the PA3-17 injection product, aimed at enhancing its product portfolio in the innovative drug market [14][15]

Core Viewpoint - Awei Technology Co., Ltd. has announced that its wholly-owned subsidiary, Hunan Awei Medical Testing Co., Ltd., has obtained a medical institution practice license, allowing it to provide third-party medical testing services, which is expected to create a new growth point for the company [1][2]. Group 1: License Acquisition - Hunan Awei Medical Testing Co., Ltd. received the medical institution practice license from the Health and Health Bureau of Hunan Xiangjiang New District [1]. - The license is valid from November 4, 2025, to November 3, 2030, and covers various diagnostic specialties including clinical microbiology and clinical chemistry [1]. Group 2: Impact on Business - The acquisition of the license enables the company to integrate its existing testing instruments and reagents with testing services, promoting a "device + service" business model [2]. - The impact on the company's performance post-launch of the testing laboratory remains uncertain due to factors such as industry supply and demand, market competition, and brand promotion [2]. Group 3: Investor Communication - The company will hold a third-quarter performance briefing on November 24, 2025, to discuss its operational results and financial status, allowing investors to engage in Q&A [6][7]. - Investors can submit questions from November 17 to November 21, 2025, through the Shanghai Stock Exchange Roadshow Center [8].

Core Points - Awei Technology announced that its wholly-owned subsidiary, Hunan Awei Medical Laboratory Co., Ltd., has received a medical institution practice license from the Health Bureau of Hunan Xiangjiang New Area [2] Group 1 - The license allows the subsidiary to operate as a medical institution, which may enhance its service offerings and market presence [2]

证券代码：688067 证券简称：爱威科技 公告编号：2025-047 爱威科技股份有限公司 关于子公司取得医疗机构执业许可证的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 有效期限：自 2025 年 11 月 04 日至 2030 年 11 月 03 日 诊疗科目：医学检验科；临床体液、血液专业；临床微生物学专业；临床化 学检验专业；临床免疫、血清学专业；临床细胞分子遗传学专业******。 二、本次获证对公司的影响 本次湖南爱威医学检验所有限公司获得医疗机构执业许可证，未来将正式对 外提供第三方医学检验服务。这不仅为公司开辟了新的业务增长点，更有助于将 公司现有的检验仪器、试剂耗材与检验服务深度融合，打造"设备+服务"一体化 的商业模式。 爱威科技股份有限公司（以下简称"公司"）全资子公司湖南爱威医学检验 所有限公司于近日收到湖南湘江新区管理委员会卫生健康局签发的《中华人民共 和国医疗机构执业许可证》。现将相关事项公告如下： 一、执业证书主要内容 机构名称：长沙爱威医学检验实验室 地 址：湖南省长沙 ...